Literature DB >> 20061586

Hemolytic uremic syndrome.

Sushmita Banerjee1.   

Abstract

CONTEXT: Hemolytic uremic syndrome (HUS) is a severe acute disease, sometimes with long-term sequelae. The diarrhoea-unrelated forms are particularly associated with a poor prognosis. The aim of this paper is to review current evidence regarding etiology and management, and explore methods by which the outcome may be optimized. EVIDENCE ACQUISITION: An internet search of Medline, Medscape, MDConsult and Cochrane databases for publications related to HUS from 1998 onwards was performed. A review of articles pertaining to etiopathogenesis and management was undertaken.
RESULTS: HUS is now classified according to cause. New assays and gene studies allow exact diagnosis of many of the atypical forms. Post-exposure prevention of diarrhoea associated HUS with vaccines and toxin-binding agents, remains in the experimental stages. Specific directed therapies aimed at replacing deficient factors can improve the outcome of atypical HUS.
CONCLUSIONS: Supportive care remains the cornerstone of management of HUS. The infection-unrelated forms should in addition be treated rapidly with plasma therapy. Efforts should be made to make an exact etiological diagnosis in all patients, as long-term treatment and prognosis is affected. Prevention of diarrhea-associated HUS by improving sanitation and proper attention to food hygiene is a practical goal.

Entities:  

Mesh:

Year:  2009        PMID: 20061586

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  2 in total

1.  Streptococcus pneumoniae-associated Hemolytic Uremic Syndrome.

Authors:  Suresh Kumar Angurana; Ankit Mehta; Triptee Agrawal; Karthi Nallasamy; Muralidharan Jayashree
Journal:  Indian J Pediatr       Date:  2018-02-08       Impact factor: 1.967

2.  Lessons learned from hemolytic uremic syndrome registries: recommendations for implementation.

Authors:  Mina Lazem; Abbas Sheikhtaheri; Nakysa Hooman
Journal:  Orphanet J Rare Dis       Date:  2021-05-25       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.